10-Q: ImmunityBio Reports Q3 2024 Results, ANKTIVA Sales Begin

ImmunityBio reports its Q3 2024 results, highlighting the start of ANKTIVA sales and ongoing clinical development.

Summary

• ImmunityBio reported a net loss of $85.7 million for the third quarter of 2024, compared to a net loss of $95.6 million for the same period in 2023.
• The company's product revenue, net, was $5.95 million for the quarter, reflecting the initial sales of ANKTIVA after its FDA approval in April 2024.
• Research and development expenses were $50.4 million for the quarter, a slight increase from $48.4 million in the same period of 2023.
• Selling, general, and administrative expenses were $35.9 million for the quarter, up from $31.8 million in the same period of 2023.
• The company's cash and cash equivalents totaled $112 million as of September 30, 2024, down from $265.5 million at the end of 2023.
• The company has an accumulated deficit of $3.3 billion as of September 30, 2024.
• The company believes its existing cash and cash equivalents, investments in marketable securities, sales of its approved product, capital to be raised through equity offerings, and potential ability to borrow from affiliated entities will be sufficient to fund its operations through at least the next 12 months.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the start of ANKTIVA sales is a positive development, the company's significant losses, high cash burn, and reliance on future funding raise concerns. The sentiment is cautiously optimistic but with significant risks.

Positives

• The company has begun generating revenue from ANKTIVA sales.
• The company has secured coverage for over 200 million medical lives through medical reimbursement policies.
• The company has extended the shelf life of ANKTIVA drug product to three years.
• The company has submitted an MAA for ANKTIVA in the UK and intends to submit an MAA in the EU.
• The company has access to additional capital through its at-the-market offering program and shelf registration statement.

Negatives

• The company continues to incur significant operating losses.
• The company's cash and cash equivalents have decreased significantly.
• The company has a substantial accumulated deficit.
• The company is dependent on additional funding or financial support to continue as a going concern.
• The company's revenue interest liability and related interest expense are significant.

Risks

• The company's ability to continue as a going concern is dependent on additional funding or financial support.
• The company's revenue interest liability and related interest expense may materially impact its financial position.
• The company's debt and revenue interest liability could limit its flexibility to raise additional capital.
• The company is dependent on the successful commercialization of ANKTIVA and the regulatory approval of its other product candidates.
• The company relies on third parties for clinical trials, manufacturing, and other essential services.
• The company is subject to extensive healthcare and other government regulations.
• The company may be unable to obtain, maintain, protect, and enforce its intellectual property rights.
• The company's stock price may be volatile and subject to dilution.
• The company is controlled by Dr. Soon-Shiong, whose interests may conflict with other stockholders.

Future Outlook

The company believes its existing cash and cash equivalents, investments in marketable securities, sales of its approved product, capital to be raised through equity offerings, and potential ability to borrow from affiliated entities will be sufficient to fund its operations through at least the next 12 months.

Industry Context

The report reflects ImmunityBio's transition from a development-stage company to a commercial entity with the launch of ANKTIVA, while also highlighting the ongoing challenges and risks associated with the biotechnology industry, including regulatory hurdles, competition, and financial sustainability.

Comparison to Industry Standards

• The company's revenue is in line with other companies that have recently launched their first product.
• The company's R&D expenses are typical for a company with multiple clinical programs.
• The company's cash burn is high, which is common for companies in the biotechnology industry that are still in the early stages of commercialization.
• The company's reliance on related-party funding is not uncommon for companies with a controlling shareholder.

Legal Proceedings

• The company is involved in ongoing litigation with Shenzhen Beike Biotechnology Co. Ltd.
• The company is subject to a securities class action lawsuit.
• The company is subject to a shareholder derivative action.

Related Party Transactions

• The company has significant related-party debt with entities affiliated with Dr. Soon-Shiong.
• The company has a shared services agreement with NantWorks.
• The company has agreements with Immuno-Oncology Clinic, Inc. for clinical trials.
• The company has a supply agreement with NantBio, Inc.
• The company has lease agreements with 605 Doug St, LLC, Duley Road, LLC, 605 Nash, LLC, and 420 Nash, LLC.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's financial situation.
• Employees may be affected by potential cost-cutting measures or changes in the company's direction.
• Customers (patients and healthcare providers) may benefit from the availability of ANKTIVA but face uncertainty regarding its long-term availability and cost.
• Suppliers and creditors face the risk of non-payment or delayed payments due to the company's financial challenges.

Next Steps

• Continue commercialization of ANKTIVA.
• Pursue regulatory approvals for ANKTIVA in other jurisdictions.
• Advance clinical development of other product candidates.
• Seek additional funding to support operations.

Key Dates

Keywords

ImmunityBio, ANKTIVA, NMIBC, cancer, immunotherapy, clinical trials, FDA, revenue, biotechnology, pharmaceutical